Skip to content

Clinical trials

Observational Barrett Esophagus trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Barrett Esophagus Phase: Observational Clear all

118 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20023
20031
20044
20053
20063
20079
20084
20094
20107
20118
20124
20137
20144
20154
20166
20178
20183
20194
20205
20215
20224
20237
20242
20255
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed54
Unknown status20
Recruiting18
Terminated12
Enrolling by invitation6
Active, not recruiting3
Not yet recruiting2
Withdrawn2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Mayo Clinic20
Midwest Biomedical Research8
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)5
CDx Diagnostics5
University of North Carolina, Chapel Hill5
Columbia University4
Johns Hopkins University4
Massachusetts General Hospital4
University of Colorado, Denver3
Imperial College London2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Barrett Esophagus118
Gastroesophageal Reflux39
Esophageal Neoplasms26
Stomach Neoplasms5
Esophageal Diseases4
Esophagitis, Peptic4
Heartburn3
Deglutition Disorders2
Disease2
Duodenal Neoplasms2

Trials

Showing 26 to 50 of 118. Each trial links to its page on Pharma Observatory.

18 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.